NCT07548268Recruiting
Transoral and Cervical Ultrasound of Patients With Suspected Oropharyngeal Cancer
Surgeon-performed Transoral and Cervical Ultrasound of the Palatine and Lingual Tonsils in Patients With Suspected Oropharyngeal Cancer - a Research Proposal for a Multicenter, Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
Introduction The current diagnostic approach for patients with suspected oropharyngeal cancer involves a combination of clinical examination, tissue sampling, and relevant cross-sectional imaging. Previous studies have shown that transoral and cervical ultrasound (US) of the palatine and lingual tonsils has a better diagnostic accuracy than clinical investigation and magnetic resonance imaging (MRI) in patients with suspected oropharyngeal cancer, but it has not been established whether adding this scan to the diagnostic workup has a clinical impact. Methods A randomized controlled study, including 170 patients at four different Head and Neck Hospital departments in Denmark. One group receives standard diagnostics (control group), and the other group receives standard diagnostics supplemented by transoral and cervical ultrasound of the lingual and palatine tonsils. The diagnostic accuracy, number of correct biopsies, number of imaging modalities ordered, and time to final diagnosis are noted. Conclusion This randomized controlled study examines whether the implementation of transoral and cervical ultrasound of the palatine and lingual tonsils in patients with suspected oropharyngeal cancer will improve the diagnostic accuracy and have a clinical impact. This concerns more accurate initial diagnoses, more correct biopsies, fewer unnecessary scans, and fewer visits to the outpatient clinic.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- First submitted
- 23 Jan 2026
- Start date
- 20 Aug 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Tobias Todsen
- Diseases
- Head and neck cancer
- NCT number
- NCT07548268
What you commit to
- Study type: Interventional
- Planned participants: 180
- From 20 Aug 2025 to the primary completion date, 1 Nov 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- • Prior oropharyngeal cancer
- Prior radiation to the head and neck area
Who the study is looking for
- Referred to outpatient cancer clinic with one of the following:
- A scan (MR, CT, PET/CT) suggesting malignancy in the oropharynx. This being asymmetric metabolic activity on PET/CT, a tumor or asymmetry of the palatine and lingual tonsils on MR and CT (7).
- Tumor suspicious findings (erosion/ulcus, tonsil asymmetry/hypertrophy).
- Tumor-suspicious symptoms (pain of the oropharynx)
- \> 18 years of age.
- Ability to understand and give informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Otorhinolaryngology, Head and Neck Surgery, Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Not yet recruiting |
| Department of Otorhinolaryngology, Head and Neck Surgery & Audiology Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
| Department of Otorhinolaryngology, Head and Neck Surgery & Audiology Northzealand Hospital Coordinator of this site? Confirm its status | Hillerød | Denmark | Not yet recruiting |
| Department of ORL - Head & Neck Surgery and Audiology, Zealand University Hospital, Coordinator of this site? Confirm its status | Køge | Denmark | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.